Add-on Acquisition • Plastics

Aptar Acquires Weihai Hengyu Medical Products

On July 28, 2021, Aptar acquired plastics company Weihai Hengyu Medical Products

Acquisition Context
  • This is Aptar’s 1st transaction in the Plastics sector.
  • This is Aptar’s 2nd transaction in China.

Explore All 474 Add-on Acquisition Plastics Deals - Search the Database Free


M&A Deal Summary

Date July 28, 2021
Target Weihai Hengyu Medical Products
Sector Plastics
Buyer(s) Aptar
Deal Type Add-on Acquisition

Target Company

Weihai Hengyu Medical Products

Weihai, China
Weihai Hengyu Medical Products is a manufacturer of elastomeric and plastic components used in injectable drug delivery. Hengyu was founded in 1998 and has approximately 150 employees at its facility in Weihai, China.
Explore More Deals

Browse All 215,158 Deals

FILTER BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Search Free

Buyer Overview 1

Buyer

Aptar

Crystal Lake, Illinois, United States

Category Company
Founded 1992
Sector Consumer Products
Employees13,500
Revenue 3.6B USD (2024)
DESCRIPTION

Aptar is a provider of innovative dispensing systems for personal care, fragrance, cosmetic, pharmaceutical, household, food, and beverage markets. Aptar was founded in 1992 and is based in Crystal Lake, Illinois.


Deal Context for Buyer #
Overall 13 of 15
Sector: Plastics 1 of 1
Type: Add-on Acquisition 11 of 13
Country: China 2 of 2
Year: 2021 1 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2020-02-14 FusionPKG

Dallas, Texas, United States

Fusion Packaging I LP is a provider of color cosmetics packaging, and conception-to-launch turnkey solutions for the North American beauty market. Fusion Packaging was founded in 2004 and is based in Dallas, Texas.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2021-09-02 Voluntis

Suresnes, France

Voluntis creates digital therapeutics that empower people with chronic conditions to self-manage their treatment every day, thus improving real-world outcomes. The company's solutions, combining mobile and web apps, use clinical algorithms to deliver personalized recommendations to patients and their care teams. Leveraging its Theraxium technology platform, Voluntis has designed and operates multiple digital therapeutics, especially in oncology and diabetes. It has long-standing partnerships with leading life science companies. Voluntis was formed in 2001 and is based in Cambridge, MA, and Paris, France.

Buy -

Explore Related M&A Activity